Toll Free: 1-888-928-9744

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 41 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
- The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) Overview 6 Therapeutics Development 7 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Stage of Development 7 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Therapy Area 8 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Indication 9 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Products Glance 10 Early Stage Products 10 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Companies 11 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Universities/Institutes 13 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Companies Involved in Therapeutics Development 20 ALSP, Inc. 20 BioMAS Ltd. 21 Oncomatryx Biopharma, S.L. 22 Phelix Therapeutics, LLC 23 Virobay Inc. 24 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Drug Profiles 25 ALP-496 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CIBP-4 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 OMTX-001 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 SAS - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecules to Activate Cathepsin B for Alzheimer's Disease - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VBY-129 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 VBY-285 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 VBY-376 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 VBY-825 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Dormant Projects 37 Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Featured News & Press Releases 38 Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent 38 Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico 38 Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by ALSP, Inc., H1 2016 20 Pipeline by BioMAS Ltd., H1 2016 21 Pipeline by Oncomatryx Biopharma, S.L., H1 2016 22 Pipeline by Phelix Therapeutics, LLC, H1 2016 23 Pipeline by Virobay Inc., H1 2016 24 Dormant Projects, H1 2016 37


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify